Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 415

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 415
---
 included by a target business as a condition to any agreement with respect to our initial business combination. •Our initial stockholders, officers or directors may have a conflict of interest with respect to evaluating a business combination and financing arrangements as we may obtain loans from our initial stockholders or an affiliate of our initial stockholders or any of our officers or directors to finance transaction costs in connection with an intended initial business combination. Up to $1,500,000 of such loans may be, at the option of the lender, convertible into placement warrants at a price of $1.00 per warrant. Such units would be identical to the private placement warrants, including as to exercise price, exercisability and exercise period. 224

•Our initial stockholders, officers and directors may be owed reimbursement for expenses incurred in connection with certain activities on our behalf which would only be repaid if we complete an initial business combination. •Our officers and directors may be paid consulting, finder or success fees for assisting us in consummating our initial business combination. The conflicts described above may not be resolved in our favor. In general, officers and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation if: •the corporation could financially undertake the opportunity; •the opportunity is within the corporation’s line of business; and •it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation. We are not prohibited from pursuing an initial business combination with a company that is affiliated with our initial stockholders, officers or directors. In the event we seek to complete our initial business combination with such a company, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm which is a member of FINRA, or from an independent accounting firm, that such an initial business combination is fair to our company from a financial point of view. In the event that we submit our initial business combination to our public stockholders for a vote, our sponsor, executive officers, and directors have agreed to vote their founder shares and any public shares purchased in or after our initial public offering in favor of our initial business combination. The following table summarizes the relevant pre -existingfiduciary or contractual obligations of our officers and directors:

| Individual     |     | Entity                                                        |     | Position at affiliated entity |
| Jack Stover    |     | Traws Pharma Inc. (Traw) formerly Onconova Therapeutics, Inc.